How We Treat HER2-Positive Metastatic Breast Cancer

Introduction Overexpression of the human epidermal growth factor receptor-2 (HER2), or amplification of the HER2 gene, is seen in approximately 15 to 25% of all breast cancer patients.[ 1 ] Real-world data from hospital-based cohorts estimated a prevalence of 23%.[ 2 ] Far more patients in India present with advanced disease when compared with high-income countries. In this narrative review, we describe the current landscape of HER2 targeting. We focus on how we treat HER2-positive metastatic breast cancer (MBC). Publication History Article published online: 26 November 2021 © 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Thieme Medical and Scientific Publishers Private Ltd. A-12, Second Floor, Sector -2, NOIDA -201301, India